Market TodayThemes and Stocks SummaryThematic Stock SearchDaily Refresh Schedule
NVTA - Invitae Corp
1.70(4.98%)8:55:08 PM 3/8/2021
Invitae Corporation, a medical genetics company, processes DNA-containing samples, analyzes information related to patient-specific genetic variation, and generates test reports for clinicians and their patients in the United States, Canada, and internationally. It offers genetic tests in various clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, metabolic conditions, and rare diseases; prenatal and perinatal genetic tests; and non-invasive prenatal screening products. The company also provides preimplantation and carrier screening for inherited disorders; products for prenatal diagnosis, miscarriage analysis, and pediatric developmental disorders; a platform for collecting, curating, coordinating, and delivering data from patients and clinicians; and CancerGene Connect, a platform for collecting and managing genetic family histories to deliver personalized genetic risk information. It serves patients, healthcare providers, and biopharma and advocacy partners. Invitae Corporation has a collaboration with Gene Therapies Ltd. for the detection of lysosomal storage disorders in children; and a research collaboration with Pacific Biosciences of California, Inc. for the investigation of clinically relevant molecular targets for use in the development of advanced diagnostic testing for epilepsy. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was founded in 2010 and is headquartered in San Francisco, California.
Stock Chart

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 


Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.


  • Volume Zscore is a recent 2 week high. A recent surge of ZScore means trading activities is accelerating at a record speed.
  • Volatility is at a recent 2 week high. A high volatility of stock movement indicates uncertainty.
Stock Statistics
PE Ratio
PEG Ratio-3.2
P/S (ttm)27.4
Earning Growth (QoQ)
Revenue Growth (QoQ)
Short %13%
Held by Institutions %73%
1 Day Vol Adjusted Return-1.1
1 Month Vol Adjusted Return-7.3
3 Month Vol Adjusted Return-6.1
6 Month Vol Adjusted Return-1.6
20 Days SMA Price ZScore-2.0
50 Days SMA Price ZScore-2.7
12 -26 Days PPO-7.8
1 Month Average Short Volume Ratio39.4
1 Day Volume Change ZScore2.7
1 Month Daily Vol4.7
Related Topics

Stock news

    Does Invitae Have a Path to Profitability?

    Invitae (NYSE: NVTA) is growing revenue quickly thanks to its acquisition of ArcherDx, which offers tests to determine the best drugs to treat tumors. In this video from Motley Fool Live, recorded on Feb. 22, contributors Brian Orelli and Keith Speights discuss how Invitae's top-line growth should eventually benefit the company's bottom line.

    Why Invitae Stock Tumbled Again Today

    Shares of Invitae (NYSE: NVTA) were down 8.6% as of 3:30 p.m. EST on Thursday. Invitae hasn't announced any news that would cause its shares to slump. Investors shouldn't be alarmed by Invitae's pullback.

    Invitae to Present at the Oppenheimer 31st Annual Healthcare Conference

    Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that members of its management team will present at the Oppenheimer 31st Annual Healthcare Conference on Tuesday, March 16, 2021 at 10:40 a.m. Eastern / 7:40 a.m. Pacific.

    Should You Buy Invitae Stock?

    The past 12 months have been a wild ride for the genetic testing company's stock, with a sub-$10 low and a high of more than $60.

    Why Invitae Stock Fell Today

    What happened Shares of Invitae (NYSE: NVTA) had fallen 6.6% as of 3:13 p.m. EST on Wednesday. The medical genetics company didn't announce any news that would cause the stock to drop. Instead, Invitae's decline today appears to be part of a broader sell-off of high-growth stocks, with the Nasdaq Composite Index falling 2%.

    Pharming Group, in collaboration with Invitae Corporation, launches genetic testing program 'navigateAPDS' in US and Canada

    Pharming Group N.V. ("Pharming" or "the Company") (Euronext Amsterdam: PHARM/Nasdaq: PHAR), a global, commercial stage biopharmaceutical company developing innovative protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs, in collaboration with Invitae Corporation (NYSE: NVTA, "Invitae"), a leading medical genetics company, announces the launch of a sponsored genetic testing program, navigateAPDS, designed to assist clinicians in identify...

    Invitae adds Medneon's risk assessment tools to its education and clinical support offerings

    Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced the addition of tools from Medneon, a digital health AI company, to its robust clinical workflow and patient education tools. The additional capabilities further support clinicians and patients with cancer by making it easier to determine who should get testing and how to use genetic information to individualize treatment.

    Is There An Opportunity With NEXT plc's (LON:NXT) 31% Undervaluation?

    Today we'll do a simple run through of a valuation method used to estimate the attractiveness of NEXT plc ( LON:NXT...

    Why Invitae Stock Is Falling Today

    Invitae's stock was down by 8.4% as of 1:06 p.m. EST today, after falling by as much as 15.2% earlier in the day. Instead, Invitae is likely guilty of general stock market volatility. As of this writing, all three major U.S. stock market indexes are down.

    Invitae expands capabilities of its advanced clinical chatbot Gia, enhancing telemedicine support for patients and clinicians

    Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced expanded capabilities that enable clinicians to use its advanced clinical chatbot Gia to guide their patients in an intuitive, enjoyable and telemedicine-friendly conversation through receiving and understanding genetic test results and possible next steps, including scheduling a call with a genetics counselor.